EUVIMEDEUVIMED entdecken
Crossref

Durvalumab and taxane family combination therapy enhances the antitumoral effects for NSCLC: An in vitro study

Mohammad-Reza Firoozi iD, Sanam Sadeghi-Mohammadi, Milad Asadi, Najibeh Shekari, Farshad Seyed Nejad, Mostafa Alizade-Harakiyan, Zahra Soleimani, Habib Zarredar

Cell Biochemistry and Function · 2024

DOI: 10.1002/cbf.3919 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Biochemistry and Function, 2024. Verfasst von Mohammad-Reza Firoozi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Tuberculosis and Lung Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal, Bridged-Ring Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Tuberculosis and Lung Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has lately become the most preferred cancer treatment method, and for non‐small cell lung cancer (NSCLC) first‐line treatment, there are many immunotherapy options. This study aimed to assess the effectiveness and toxicity of paclitaxel (PTX), docetaxel (DTX) chemotherapy, immune checkpoint inhibitor treatment (durvalumab; DVL), and their combination in NSCLC. A‐549 cells were treated with DVL in combination with PTX and DTX (a quarter of the IC 50 ) to investigate their anticancer effects on these cells. The MTT assay, wound healing tests, and double‐staining with Annexin V/PI were used to assess the cell viability, apoptosis, and migration. The results showed that a combination of 0.35 mg/mL DVL with 6.5 μg/mL PTX and 1.75 μg/mL DTX produced a synergistic effect with CI values of 0.88, 0.37, and 0.81, respectively. Moreover, the PTX + DTX + DVL combination led to a significantly increased apoptotic rate up to 88.70 ± 3.39% in the A549 cell line compared to monotherapy ( p < .001). In addition, we found that the combination therapy with these agents increased the expression level of Bax, Cas‐3, p53, and Bax/Bcl‐2 ratio in all experimental groups. In conclusion, the results suggest that combining anti‐PD‐L1 antibody therapy with chemotherapy may provide a promising approach to enhance treatment outcomes and be a potentially efficacious strategy for treating NSCLC patients. Further research and clinical investigations are needed to elucidate the underlying molecular mechanisms and validate the therapeutic potential of these compounds in vivo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, MonoclonalBridged-Ring CompoundsHumansbcl-2-Associated X ProteinTaxoidsDocetaxelPaclitaxel

Stichwörter der Autor:innen

combination therapydocetaxeldurvalumabimmunotherapynon-small cell lung cancer (NSCLC)paclitaxel

Substanzen

durvalumabbcl-2-Associated X ProteintaxaneTaxoidsDocetaxelPaclitaxelAntibodies, MonoclonalBridged-Ring Compounds

Autor:innen und Institutionen

  • Tuberculosis and Lung Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Department of Basic Oncology, Health Institute of Ege University, Izmir, Turkey.
  • Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Radiation Oncology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

ORCID-Profile: Mohammad-Reza Firoozi

Förderung

  • Tuberculosis and Lung Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Zitieren

APA

Firoozi, M. R., Sadeghi-Mohammadi, S., Asadi, M., Shekari, N., Seyed Nejad, F., Alizade-Harakiyan, M., Soleimani, Z., & Zarredar, H. (2024). Durvalumab and taxane family combination therapy enhances the antitumoral effects for NSCLC: An in vitro study. Cell Biochemistry and Function. https://doi.org/10.1002/cbf.3919

Vancouver

Firoozi MR, Sadeghi-Mohammadi S, Asadi M, Shekari N, Seyed Nejad F, Alizade-Harakiyan M, et al. Durvalumab and taxane family combination therapy enhances the antitumoral effects for NSCLC: An in vitro study. Cell Biochemistry and Function. 2024. doi:10.1002/cbf.3919

BibTeX
@article{Firoozi2024,
  author = {Firoozi, Mohammad-Reza and Sadeghi-Mohammadi, Sanam and Asadi, Milad and Shekari, Najibeh and Seyed Nejad, Farshad and Alizade-Harakiyan, Mostafa and Soleimani, Zahra and Zarredar, Habib},
  title = {Durvalumab and taxane family combination therapy enhances the antitumoral effects for NSCLC: An in vitro study},
  journal = {Cell Biochemistry and Function},
  year = {2024},
  doi = {10.1002/cbf.3919}
}
Kostenlos starten →